Cell Harvesting Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Cell Harvesting Market Trends and Insights

Growing Investment in Cell and Gene Therapies

More than USD 2.3 billion in equity has entered cell and gene therapy ventures during the last decade, underpinning over 1,500 active clinical studies worldwide^{[1]Journal of Translational Medicine, “Global Cell Therapy Market Forecast,” translational-medicine.biomedcentral.com}. The FDA cleared eight novel advanced therapies in 2024, including the first mesenchymal stromal cell product, Ryoncil, demonstrating regulatory confidence in complex biologics^{[2]U.S. Food and Drug Administration, “Cellular & Gene Therapy Guidance Documents,” fda.gov}. Pharmaceutical majors are scaling quickly: Bristol Myers Squibb opened three dedicated CAR-T plants, and AstraZeneca spent USD 425 million for EsoBiotec to accelerate in vivo programs. Capital inflows shorten development timelines and increase the volume of autologous and allogeneic batches that require reliable, high-throughput harvesters. Investors now prioritize platforms that can support multiproduct pipelines, lifting the appeal of integrated harvest devices with modular add-ons.

Expansion of Biopharmaceutical Manufacturing Infrastructure

Fujifilm Diosynth’s USD 1.6 billion Denmark-Texas expansion adds eight 20,000 L bioreactors and specialized downstream suites, while Lotte Biologics is committing USD 1 billion for its Songdo Bio Campus to reach 120,000 L capacity by 2027. Such mega-projects create regional clusters that need harvesters compatible with both single-use and stainless-steel trains. Many CDMOs still operate at less than 50% utilization, prompting demand for flexible systems that can cost-effectively handle clinical-scale autologous lots today and pivot to large allogeneic runs tomorrow. Suppliers offering modular skid architecture with interchangeable centrifugation or filtration elements address this utilization gap and can be rapidly redeployed as production priorities change.

Rising Prevalence of Chronic Diseases Requiring Cell Therapies

Cancer incidence and refractory hematological conditions continue to rise, expanding the pool of patients who may benefit from CAR-T and NK-cell therapies. Autologous treatment protocols demand time-critical harvesting of functional cells, motivating oncology centers to deploy closed, sterile harvest workstations. Parallel growth in orthopedic and cardiovascular regenerative applications fuels demand for large, high-quality mesenchymal stromal cell yields. Demographics in North America, Europe, and high-income Asian economies magnify this trend, as aging populations require novel regenerative interventions. Providers that can deliver consistent, viable harvests despite patient-to-patient variability are well placed to capture clinician trust.

Technological Advancements in Automated Cell Processing

Terumo BCT’s Quantum Flex system cuts harvest time by 88% relative to manual flasks while preserving >90% viability. Cellares reports 760% throughput gains and 80% floor-space savings with its Cell Shuttle compared with traditional laminar-flow suites. Sartorius’ Ksep instrument achieves >90% cell recovery under low-shear conditions, reducing contamination risks through single-use chambers. Emerging AI layers adjust spin speed and buffer exchanges in real time, lowering error rates that currently range from 4–10% in commercial CAR-T batches. Smaller footprints, lower headcount requirements, and digital batch records combine to improve cost-of-goods and regulatory traceability.

Ethical and Regulatory Concerns Around Stem Cell Sourcing

Embryonic stem cell research and unproven adipose-derived procedures face increased oversight after U.S. appellate courts confirmed that reinjected cells fall under FDA biologics regulation. Divergent donor screening rules in the EU, United States, and Asia complicate multinational studies and raise documentation costs. Unlicensed clinics advertising miracle cures in regions with light enforcement undermine public confidence, prompting regulators to publish warning letters and mandate clinic closures. Compliant suppliers that document ethical sourcing and GMP provenance can differentiate, but they must navigate evolving consent requirements and tissue-bank audits that vary by country.

High Cost of Automated Harvesting Systems

Top-tier automated harvesters often exceed USD 1 million per unit, and annual validation plus service contracts add further burden. Smaller biotechs, early-stage academic labs, and emerging-market hospitals frequently lack capital to purchase such systems, postponing adoption. Manufacturing-as-a-service models are easing the pain: Cellares offers pay-per-batch access to its Cell Shuttle, eliminating upfront investment. Competitive pressure has spurred development of modular harvesters priced 20–30% below flagship devices, but the need for trained technicians and validated clean utilities continues to slow uptake in low-resource settings.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Type of Cell Harvesting: Automation Drives Market Evolution

Automated systems held 62.85% of the cell harvesting market share in 2025 thanks to closed, programmable workflows that cut labor hours and contamination risk. They are projected to record a 14.92% CAGR through 2031. Manual harvesters remain relevant for exploratory work or highly variable early-phase protocols that benefit from hands-on manipulation. However, even academic labs are adopting semi-automated modules that bolt onto legacy incubators, blending tactile oversight with digital monitoring. Industry-wide migration toward continuous processing and single-use assemblies will likely elevate automated systems to more than 70% of the cell harvesting market size by decade’s end.

Automation’s momentum aligns with factory digitization goals. Vendors are bundling integrated centrifugation, filtration, and washing in one chassis to streamline line clearance and validation. Remote diagnostics and software updates provide shorter downtimes and keep performance within specification. Suppliers able to certify systems in multiple jurisdictions and offer 24-hour parts support gain a competitive edge as global trials expand.

By Application: Biopharmaceutical Dominance with Research Acceleration

Commercial biologics accounted for 49.23% of the 2025 revenue pool, supported by an increasing number of on-market CAR-T products and regulatory approvals for next-generation allogeneic candidates. Autologous oncology programs drive batch volumes that must meet stringent sterility and timeline targets, reinforcing demand for robust harvest platforms. Meanwhile, stem-cell and regenerative medicine research is the fastest-growing application, advancing at a 16.05% CAGR to 2031. Investment in induced pluripotent stem cell lines, 3D organoid models, and CRISPR-edited therapeutics boosts laboratory harvesting requirements. High-throughput screen-expansion-harvest combinations permit scientists to analyze hundreds of cell lines per week, accelerating lead identification.

Cross-disciplinary convergence blurs historical boundaries. Vaccine developers adapting cell-based production, exosome therapy startups, and protein deuteration specialists are adopting the same harvest infrastructure. Vendors certified for multi-mode payloads gain preferential status because clients can amortize equipment across several programs. As product pipelines diversify, harvesters capable of switching from T lymphocytes to MSCs with minimal cleaning or changeover time become essential.

By End User: Biotech Leadership with Academic Growth

Biotechnology and biopharmaceutical companies represented 51.84% of 2025 demand due to their focus on late-stage trials and commercial launches that require cGMP harvest capacity. They prefer integrated, high-throughput suites featuring automated cell collection, concentration, and buffer exchange modules. Academic and government institutes are the fastest-growing end user group, expanding at 15.67% CAGR, fueled by public grants and collaborative research initiatives. Canada’s USD 22.5 million grant to STEMCELL Technologies for a GMP plant exemplifies this support. Hospitals and specialized treatment centers are piloting PoC manufacturing, often via containerized cleanrooms that host compact harvesters. Suppliers offering turnkey service packages—compliance documentation, operator training, remote monitoring—stand to expand market reach among resource-constrained centers.

Geography Analysis

North America held 38.95% of global revenue in 2025, supported by a mature CGT regulatory framework, extensive CDMO network, and specialized logistics operators. Yet fewer than 20% of eligible U.S. patients accessed available therapies in 2024, underscoring process inefficiencies that automated harvesters can mitigate. Regional growth also depends on skilled labor supply, prompting partnership programs between equipment vendors and community colleges to cultivate technicians.

Asia-Pacific is projected to expand at 14.11% CAGR to 2031. China hosted 37% of global CGT trials in 2024, and Japan’s Fast Track and South Korea’s Regenerative Medicine Law cut approval timelines. Domestic players like WuXi AppTec and SK Bioscience have invested heavily in CGT hubs, driving bulk orders for harvest modules compatible with local GMP guidelines. Lower operating costs, government incentives, and rising chronic-disease prevalence amplify demand, but suppliers must adapt to evolving import regulations and multilingual quality documentation.

Europe maintains a sizable share anchored by harmonized EMA guidelines and robust CDMO infrastructure in Denmark, Ireland, and Germany. Fujifilm Diosynth’s Danish plant expansion exemplifies continued capital inflow aimed at increasing regional self-sufficiency. Energy costs push facilities to adopt energy-efficient harvesters with shorter cycle times. The Middle East & Africa and South America are emerging opportunity zones as healthcare systems invest in tertiary care and establish bilateral technology-transfer agreements. Compact, rugged harvesters that tolerate power fluctuations find growing reception in these regions.

Regulatory Landscape

Regulation for cell harvesting equipment and workflows is largely framed through advanced therapy and biologics requirements that emphasize GMP, closed processing, traceability, and validated analytical methods. In the United States, the FDA has continued to publish and update guidance for cellular and gene therapy products and programs aimed at modernizing early- and late-stage clinical development expectations, tightening the link between manufacturing control strategies (including harvest, wash, and concentration steps) and product quality attributes.

In Europe, the EMA maintains the legal framework for advanced therapy medicinal products (ATMPs) and is progressing updates to ATMP-focused GMP guidance, reinforcing expectations around contamination control, documentation, and comparability when processes scale or move sites. Standard-setting for harvesting-adjacent controls is also becoming more explicit: ISO published new biotechnology standards in June 2026 covering cell viability analytical methods (ISO 8934-1:2026) and cell line authentication (ISO 23511), and advanced a draft international standard in March 2026 for equipment systems used in manufacturing cellular therapeutic products (ISO/DIS 23565). Together, these updates raise the compliance bar for equipment qualification and method standardization across jurisdictions.

Market Opportunities and Future Outlook

White-space opportunities are concentrated in closing remaining manual and open processing steps around harvest, particularly where therapy developers and CDMOs want end-to-end closed workflows that reduce operator touchpoints and simplify batch records. Thermo Fisher Scientifics 2026 introductions in the Gibco CTS portfolio, including the CTS Compleo Fill and Finish System (April 2026) and an integrated platform positioned for scalable cell therapy manufacturing (May 2026), reflect ongoing buyer pull for integrated, functionally closed unit operations that reduce cleanroom burden and changeover time. ScaleReadys GatheRex launch (April 2026) targets automation of media removal and cell collection from G-Rex bioreactors, pointing to demand for purpose-built harvest automation around widely used expansion formats.

A second opportunity area is capacity build-outs and supply chain resilience efforts that reward standardized, high-throughput, single-use compatible harvesting and clarification. In July 2026, Johnson & Johnson announced a more than USD 1 billion investment in a next-generation cell therapy manufacturing facility in Pennsylvania, while AGC Biologics announced a USD 350 million Yokohama site for cell therapy and other modalities (April 2026) and Kincell Bio expanded its Research Triangle Park facility with additional ISO 7 cleanroom suites (April 2026). These moves support more multi-site tech transfers and scale-ups where harmonized harvesting equipment, validation packages, and analytical standards (including ISO activity in 2026) can become procurement differentiators, especially for CDMOs supporting both autologous and allogeneic programs.